Pharmaceutical statisticians have come a long way over the past half century, evolving from backroom number-crunchers to essential contributors across the entire drug development spectrum. Haoda Fu and Amy Xia discuss where the field may be headed.
Biopharmaceutical Report
Celebrating the 40th Anniversary of the Biopharmaceutical Section: The Early Years (1966–1990)
Over its long history, the Biopharmaceutical (BIOP) Section has fostered community and created a shared sense of purpose among statisticians in the medical product industry. The year 2021 marks the 40th anniversary of BIOP.
Biopharmaceutical Report Focuses on Statistical Issues in COVID-19 Trials
The editorial team invited authors from government, industry, and academia to write articles about their perspectives on the impact of COVID-19 on clinical trials, particularly the statistical issues involved in designing new COVID-19 trials.
A Transition Letter from Outgoing, Incoming Chairs
As 2011 has drawn to a close and 2012 begins, the outgoing and incoming Biopharmacuetical Section chairs have decided to shake things up a bit by starting a new ‘tradition’—a jointly authored transition letter. Not only will they recognize some with a well-deserved thank you, but they also will look ahead to new faces and efforts taking shape for 2012.
A Look Back and Forward
The Biopharmaceutical Section made considerable progress last year on many of its projects. Outgoing chair, Anna Nevius, discusses the section’s successess and plans for the future.